Recombinant Rat S100a9 protein, His-tagged

• Cat.No.: S100a9-1806R
• Product Overview: Recombinant Rat S100a9 aa. (Met1~Lys113 (Accession # P50116)) fused with N-terminal His tag was produced in E. coli cells.

Specification

• Description: Calcium binding protein that may be associated with acute inflammatory processes.
• Source: E. coli
• Species: Rat
• Tag: His
• Form: Freeze-dried powder
• Molecular Mass: Predicted Molecular Mass: 14.4kDa.
• Protein length: Met1~Lys113 (Accession # P50116)
• Endotoxin: <1.0EU per 1ug (determined by the LAL method)
• Purity: >95%
• Characteristic: The isoelectric point is 7.2.
• Applications: SDS-PAGE; WB; ELISA; IP.
• Stability: The thermal stability is described by the loss rate of the target protein. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. (Referring from China Biological Products Standard, which was calculated by the Arrhenius equation.) The loss of this protein is less than 5% within the expiration date under appropriate storage condition.
• Storage: Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.
• Storage Buffer: Supplied as lyophilized form in PBS, pH7.4, containing 5% trehalose, 0.01% sarcosyl.
• Reconstitution: Reconstitute in sterile PBS, pH7.2-pH7.4.

Gene Information

• Gene Name: S100a9 S100 calcium binding protein A9 [ Rattus norvegicus (Norway rat) ]
• Official Symbol: S100a9
• Synonyms: Naglu; alpha-N-acetylglucosaminidase (Sanfilippo disease IIIB); alpha-N-acetylglucosaminidase; N-acetyl-glucosaminidase; alpha-N-acetylglucosaminidase, lysosomal
• Gene ID: 94195
• mRNA Refseq: NM_053587.1
• Protein Refseq: NP_446039.1
• UniProt ID: P50116

Reviews

08/17/2021

This includes complementary reagents, protocols, and access to an extensive knowledge base, all aimed at streamlining the trial process and maximizing the chances of achieving meaningful results.

06/20/2016

By choosing the S100A9 protein and partnering with the manufacturer, researchers can confidently conduct their trials, achieve reliable results, and contribute to groundbreaking discoveries.

04/04/2016

Collaborating with the manufacturer opens up possibilities for potential collaboration and exchange of information with a wider scientific community, allowing researchers to stay at the forefront of advancements in their respective fields.

Q&As

How is S100A9 protein measured in clinical settings?

S100A9 levels can be measured using various laboratory techniques, such as ELISA (enzyme-linked immunosorbent assay).

Are there any therapies or drugs targeting S100A9 in clinical development?

Some research is exploring the development of drugs that target S100A9 to modulate inflammation, but clinical applications are still in the experimental phase.

Can S100A9 levels be used as a biomarker for specific diseases?

Yes, elevated S100A9 levels have been associated with conditions like rheumatoid arthritis and inflammatory bowel disease, making it a potential biomarker.

Can S100A9 be used to predict disease outcomes?

Elevated S100A9 levels have been linked to poorer outcomes in certain diseases, making it a potential predictor of disease severity.

Are there any genetic factors that influence S100A9 levels?

Genetic variations can influence S100A9 expression, and these variations may impact an individual's susceptibility to certain diseases.